Phase 2 Melanoma trials recruiting now

All Melanoma trials, every phase

Other phases for Melanoma

Phase 2 Melanoma trials

• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
  NCT06961006 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 38 locations
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
  NCT04370587 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Clinical Study of T3011 in Subjects With Advanced Melanoma
  NCT06214156 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 76 locations
• A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
  NCT06413680 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
  NCT07636785 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
  NCT06956690 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 107 locations
• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
  NCT02621021 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
  NCT01638676 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
  NCT06889610 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.
  NCT07448831 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase II Trial of LM103 in Advanced Melanoma
  NCT07310784 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 16 locations
• A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
  NCT06727630 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
  NCT04126876 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 33 locations
• A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
  NCT03829254 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
  NCT05970497 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 94 locations
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 57 locations
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
  NCT06594991 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of GC101 TIL in Advanced Melanoma
  NCT06703398 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
  NCT05669430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 90 locations
• A Study of IBI363 in Subjects With Advanced Melanoma
  NCT06081920 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of IBI363 in Subjects with Advanced Solid Malignancies
  NCT06281678 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
  NCT06090266 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
  NCT02332668 · Phase: Phase 1, Phase 2 · Ages: 6 Months to 17 Years · Sex: All (male and female) · 16 locations
• A Study of ST-1898 for Unresectable or Metastatic Melanoma
  NCT06359860 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of TRK-950 in Patients With Advanced Solid Tumors
  NCT05423262 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
  NCT05592626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
  NCT04511013 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 331 locations
• A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
  NCT07749586 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
  NCT06797297 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 120 locations
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
  NCT07115043 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
  NCT05361174 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 11 locations
• A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
  NCT06940739 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 5 locations
• A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
  NCT07099430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
  NCT06624644 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
  NCT03686124 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• AMT-253 in Patients With Advanced Solid Tumours
  NCT06209580 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
  NCT07063875 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Adjuvant Quisinostat in High-Risk Uveal Melanoma
  NCT06932757 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
  NCT02830724 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 1 location
• An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
  NCT07371663 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
  NCT05296564 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
  NCT03340129 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 9 locations
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
  NCT04114136 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
  NCT05969860 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
  NCT00722228 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
  NCT04771520 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
  NCT05384496 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
  NCT04752826 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
  NCT07449754 · Phase: Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 10 locations
• Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
  NCT06163820 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
  NCT05136196 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 229 locations
• Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
  NCT05026983 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
  NCT04598009 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
  NCT07410494 · Phase: Phase 1, Phase 2 · Ages: 8 Years to 85 Years · Sex: All (male and female) · 3 locations
• Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
  NCT05512481 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
  NCT06319196 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
  NCT06961357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Combination Immunotherapy Targeting Melanoma
  NCT06739226 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
  NCT06265285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Contrast-enhanced Ultrasound for Sentinel Node Detection
  NCT07310758 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
  NCT05909618 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cryoablation+Ipilimumab+Nivolumab in Melanoma
  NCT05779423 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
  NCT06953089 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
  NCT05770102 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 54 locations
• DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
  NCT05770544 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 27 locations
• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
  NCT05768178 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
  NCT07440290 · Phase: Phase 2, Phase 3 · Ages: 1 Year and older · Sex: All (male and female) · 27 locations
• DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
  NCT07288112 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
  NCT06194929 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.
  NCT07686835 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
  NCT07627698 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
  NCT07410676 · Phase: Phase 1, Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
  NCT06223659 · Phase: Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
  NCT04844528 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
  NCT07130032 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
  NCT06887088 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
  NCT03685890 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
  NCT06630611 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
  NCT07136181 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• FMT to Convert Response to Immunotherapy
  NCT05251389 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
  NCT05983237 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
  NCT05913388 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
  NCT06265025 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
  NCT06708663 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
  NCT07281924 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
  NCT04562129 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
  NCT05229614 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
  NCT05896839 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
  NCT05428007 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 4 locations
• Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
  NCT06240143 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Intratumoral N17350 in Advanced Solid Tumors
  NCT07339176 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations

Showing 100 of 182 recruiting trials.

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.